Daxor CORP (NASDAQ:DXR) CEO Michael Richard Feldschuh purchased 1,000 shares of the company’s common stock on April 8, 2026, at $9.07 per share, for a total outlay of $9,070. Following the purchase, Feldschuh directly owns 213,694 shares of Daxor.
The acquisition occurs while the company’s share price has fallen 36% year-to-date. Despite the drop, the stock displays a modest price-to-earnings ratio of 5.18 and the company reported earnings per share of $1.81 over the last twelve months.
Independent analysis from InvestingPro, which provides coverage across more than 1,400 U.S. equities and includes Pro Research Reports, indicates that the stock currently appears fairly valued relative to its Fair Value estimate.
Beyond the insider purchase, Daxor has reported several operational and financing developments. The company recorded a 45% increase in revenue for 2025 compared with the prior year. Net assets rose to $45.9 million from $35.8 million, and the company’s net asset value per share increased to $9.07 from $7.25.
In addition to these financial metrics, Daxor announced a planned regulatory reporting transition. The company intends to move from reporting under the Investment Company Act of 1940 to reporting under the Securities Exchange Act of 1934, with the change expected to be completed by the end of the second quarter pending regulatory approvals. The company links this shift to the expansion of its diagnostic technology business.
On the financing front, Daxor completed a registered direct offering of common stock that generated approximately $8.1 million in net proceeds. The offering involved the sale of 765,958 shares at $11.75 per share and was executed under the company’s shelf registration statement that became effective on January 20, 2026.
Operationally, the company also rolled out a blood volume analysis program at a cardiology facility in Southwest Ohio. The initiative uses Daxor’s ezBVA Lab workflow to provide rapid blood volume measurements.
These items together - the insider purchase, recent revenue and net asset growth, capital raise, regulatory reporting change and the clinical program launch - present a set of discrete developments for investors and stakeholders to consider. The insider transaction is small in dollar terms but increases the CEO’s direct holding, while the company’s reported financial and operational activity reflects ongoing strategic shifts tied to its diagnostic technology business.